Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


20.11.2017

1 J Neurol Sci
1 J Neurosci
3 Mult Scler
2 Nat Rev Neurol
1 PLoS One
3 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    J Neurol Sci

  1. YOUSUF F, Dupuy SL, Tauhid S, Chu R, et al
    A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    J Neurol Sci. 2017 Oct 16. pii: S0022-510X(17)34384.
    PubMed     Text format     Abstract available


    J Neurosci

  2. HU X, Huang F, Wang ZJ
    CaMKIIalpha mediates the effect of IL-17 to promote ongoing spontaneous and evoked pain in multiple sclerosis.
    J Neurosci. 2017 Nov 16. pii: 2666-17. doi: 10.1523/JNEUROSCI.2666-17.2017.
    PubMed     Text format     Abstract available


    Mult Scler

  3. AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
    PubMed     Text format     Abstract available

  4. KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
    Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
    Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
    PubMed     Text format     Abstract available

  5. UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
    Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
    PubMed     Text format     Abstract available


    Nat Rev Neurol

  6. PITAROKOILI K, Gold R
    Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Nat Rev Neurol. 2017 Nov 17. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    

  7. STANGEL M, Kuhlmann T, Matthews PM, Kilpatrick TJ, et al
    Achievements and obstacles of remyelinating therapies in multiple sclerosis.
    Nat Rev Neurol. 2017 Nov 17. doi: 10.1038/nrneurol.2017.
    PubMed     Text format     Abstract available


    PLoS One

  8. WYBRECHT D, Reuter F, Pariollaud F, Zaaraoui W, et al
    New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study.
    PLoS One. 2017;12:e0184650.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  9. TRUMBIC B, Zephir H, Ouallet JC, Le Page E, et al
    Is the Choosing Wisely(R) campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study.
    Rev Neurol (Paris). 2017 Nov 8. pii: S0035-3787(16)30428.
    PubMed     Text format     Abstract available

  10. STANKOFF B
    Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? Comments. Anti-JCV antibody index in multiple sclerosis care.
    Rev Neurol (Paris). 2017 Nov 8. pii: S0035-3787(17)30638.
    PubMed     Text format    

  11. KUBITARY A, Alsaleh MA
    Validity of Arabic version of the two-question Quick Inventory of Depression (QID-2-Ar): Screening for multiple sclerosis in an Arab environment and during the Syrian war.
    Rev Neurol (Paris). 2017 Nov 10. pii: S0035-3787(16)30131.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: